Effect of Local Urokinase on Arterial Occlusion of Lower Limbs

J-N Fiessinger; M Aiach; L Capron; M Devanlay; M Vayssairat; Y Juillet

doi:10.1055/s-0038-1650176

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1981; 45(03): 230-232
DOI: 10.1055/s-0038-1650176

Original Article

Schattauer GmbH Stuttgart

Effect of Local Urokinase on Arterial Occlusion of Lower Limbs

J-N Fiessinger

^*The Chaire de Clinique Médicale et de Pathologie Vasculaire (Pr. E. Housset), Paris, France

,

M Aiach

^**et Département d'Hémostase, Laboratoire de Biochimie (Pr. M. Leclerc) Hôpital Broussais, Paris, France

,

L Capron

^*The Chaire de Clinique Médicale et de Pathologie Vasculaire (Pr. E. Housset), Paris, France

,

M Devanlay

^**et Département d'Hémostase, Laboratoire de Biochimie (Pr. M. Leclerc) Hôpital Broussais, Paris, France

,

M Vayssairat

^*The Chaire de Clinique Médicale et de Pathologie Vasculaire (Pr. E. Housset), Paris, France

,

Y Juillet

^*The Chaire de Clinique Médicale et de Pathologie Vasculaire (Pr. E. Housset), Paris, France

› Author Affiliations

Abstract

PDF Download

Summary

Sixty nine patients were treated with local intra-arterial urokinase (37,500 U/CTA. hr^-1) for recent severe ischemia of lower limbs: 27 (40%) ultimately required amputation. The difference of amputation rate between the groups with and without thrombolysis was not significant (33% v. 42%). A biological study in 6 patients showed that local arterial plasminemia occurred in only 1 patient. Local urokinase does not strongly stimulate “endogenous” thrombolysis and enhances “exogenous” thrombolysis only very inconstantly. A better adaptation of urokinase dosage or the use of an agent with a higher affinity for fibrin might improve the efficiency of local thrombolytic therapy.

Keywords

Thrombolysis - Urokinase - Local urokinase - Lower limbs ischemia

PDF (582 kb)

References

References
1 Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978; 84: 822-834
2 Fiessinger JN, Aiach M, Brunet G, Cormier JM, Leclerc M, Housset E. Intermittent treatment with streptokinase in arterial disease of the limbs. Vasc Surg 1977; 11: 384-390
3 Fiessinger JN, Aiach M, Vayssairat M, Juillet Y, Cormier JM, Housset E. Traitement thrombolytique des artériopathies. Ann Anesthesiol Fr 1978; 19: 739-745
4 Conard J, Samama M, Milochevitch R, Horellou MH, Chabrun B, Prestat J. Complications hémorragiques au cours de 98 traitements par la streptokinase. Place de la surveillance biologique. Nouv Presse Med 1979; 08: 1319-1325
5 McNicol GP, Reid W, Bain WH, Douglas AS. Treatment of peripheral arterial occlusion by streptokinase perfusion. Br Med J 1963; 01: 1508-1512
6 Bose A, Brose SS, Hartley G. Experiences with intra-arterial streptokinase perfusion in the treatment of acute arterial thrombosis. J clin Pathol 1969; 22: 374-375
7 Dotter CT, Rösch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-37
8 Boucher BJ, Connolly EM, Farrow SC. The use of intra-arterial urokinase in a case of recurrent arterial occlusion. Postgrad Med J 1973; 49: 365-367
9 Michaud A, Aiach M, Fiessinger JN, Vayssairat M, Juillet Y. Modifications biologiques au cours de radministration locale de faibles doses d’urokinase. Nouv Presse Med 1978; 07: 3151
10 Fiessinger JN, Vayssairat M, Juillet Y, Aiach M, Janneau D, Cormier JM, Housset E. Local urokinase in arterial thromboembolism. Angiology 1980; 31: 715-720
11 Stankowiak C, Espriet G, Watel A, Soots G. Chirurgie de revascularisation et thrombolytiques “in situ” dans les ischémies sévéres des membres. Résultats préliminaires. Lille Med 1978; 23: 460-463
12 Vermylen C, Devreker RH, Verstraete M. A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerization time (FPT). Clin Chim Acta 1963; 08: 418-424
13 Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest 1972; 29: 21-37
14 Ganrot PO. Crossed immunoelectrophoresis. Scand J Clin Lab Invest 1972; 29: 39-47
15 Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
16 Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-1095
17 Ambrus CM, Markus G. Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme. Amer J Physiol 1960; 199: 491-494
18 Chesterman CN, Allington MJ, Sharp AA. Relationship of plasminogen activator to fibrin. Nature 1972; 238: 15-17
19 Collen D. On the regulation and control of fibrinolysis. Edward Kowalski. Memorial Lecture Thromb Haemostas 1980; 43: 77-89
20 Boyles PW, Meyer WH, Graff J, Ashley CC, Ripic RG. Comparative effectiveness of intravenous and intra-arterial fibrinolysis therapy. Amer J Cardiol 1960; 06: 439-446
21 Gurll NJ, Callahan W, Hufnagel HV. High-dose, short-term local urokinase for clearing femoral thrombi by vasodilation and thrombolysis. J Surg Res 1976; 20: 381-388
22 Collen D, Verstraete M. α₂-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. Thromb Res 1979; 14: 631-639
23 Johnson WC, Widrich WC, Patten DH, Asinari J, Nabseth DC. Effect of streptokinase on canine pulmonary emboli: local vs peripheral infusion. J Surg Res 1978; 24: 366-373
24 Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh 1972; 28: 65-74
25 Reber G, Giacometti N, Bouvier CA. Studies on a new tissular activator of plasminogen, extracted from pig ovary. Vié Congrés International sur la thrombose, Monte-Carlo. 1980. abstract 179